NCX-1000

NCX-1000 is a nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), designed to selectively deliver NO to the liver. It acts as a liver-specific NO donor, providing cytoprotective, antioxidant, and hypoinsulinemic effects in preclinical models. The drug has been shown in animal studies to ameliorate portal hypertension, reduce intrahepatic resistance, prevent ascite formation, and decrease collagen deposition associated with liver fibrosis and cirrhosis. Its mechanism involves increasing hepatic cGMP concentrations by releasing NO locally within the liver microcirculation, thereby counteracting endogenous vasoconstrictors and relaxing hepatic stellate cells. NCX-1000 was developed for potential use in chronic liver diseases such as cirrhosis and nonalcoholic steatohepatitis (NASH), but clinical trials have not demonstrated significant efficacy in reducing portal pressure in patients with cirrhosis[2][3][5][6][8].

Brand names

NCX 1000NCX1000NCX-1000

Other names

2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester